🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Bruker Corporation BRKR R3KPHARMA

Healthcare · Medical Devices · United States
https://www.bruker.com
Company Profile ↓
$58.37
+69.83% 1Y
Mkt Cap$8.89B
P/E-83.39
P/B3.48
Div. Yield0.34%
52W High$64.34
52W Low$29.21
Book Value$15.63
EPS (TTM)$-0.70

Company Overview

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $3.44B (+2.1% YoY); net profit $-8.60M.
  • Trailing 12 Months Year-on-year growth — revenue +5.2%, earnings -107.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:7.29%
1 Year:5.20%

Compounded Profit Growth

5 Years:-
1 Year:-107.60%

Stock Price Performance

1 Year:+69.83%
6 Months:+57.28%
3 Months:+3.84%
1 Month:+9.29%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 83% of range
$29.21 $64.34
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)50.89 · Neutral
Price Performance
1M+9.29%
3M+3.84%
6M+57.28%
1Y+69.83%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-83.39
Industry PE
24.83
Forward P/E
24.43
PEG Ratio
1.52
Book Value
$15.63
Price to Book
3.48
P/S
2.37
EV/EBITDA
19.62
Dividend Yield
0.34%

Growth (CAGR)

Revenue 5Y
7.29%
Profit 5Y
-
Revenue (YoY)
5.20%
Earnings (YoY)
-107.60%

Profitability & Returns

ROCE
1.37%
ROE
-3.00%
ROA
3.14%
Profit Margin
-2.04%
Op Margin
9.88%
Gross Margin
48.48%
EPS (Latest Qtr)
$-0.41
EPS (TTM)
$-0.70

Balance Sheet & Liquidity

Debt/Equity
0.76
Quick Ratio
0.80
Current Ratio
1.85
Debt
$1.86B
Total Assets
$6.05B
Current Assets
$2.10B
Working Capital
$748.50M

Ownership

Promoter Holding
26.97%
Chg in Prom Hold
0.04%
FII / Inst Holding
95.85%
Chg in FII Hold
-0.14%

Financial Snapshot

Enterprise Value
$8.89B
Total Revenue (TTM)
$3.50B
EBITDA
$541.10M
Free Cash Flow
$179.94M
Operating Cash Flow
$190.40M
Shares Outstanding
152.36M
Gross Margin
48.48%
Payout Ratio
38.46%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BRKR Bruker Corporation R3KPHARMA 58.37 -83.39 $8.89B 0.34% 1.37% -3.00% 7.29% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ------------431.70M443.70M466.60M553.60M461.40M490.20M521.10M599.90M424.00M424.60M511.40M554.70M570.80M608.90M595.00M588.40M638.90M685.30M681.90M742.80M721.70M800.70M864.40M801.40M797.40M860.50M823.40M838.50M
Gross Profit 160.20M169.40M167.50M211.50M166.80M170.10M185.20M220.40M176.40M184.50M198.90M256.20M199.40M205.20M222.60M272.80M214.70M230.40M253.90M296.30M192.30M186.20M248.30M278.70M280.60M308.70M306.30M298.20M335.30M359.70M340.50M382.80M352.80M384.60M418.80M391.20M357.90M379.40M379.80M416.00M
Operating Income 15.20M31.60M28.20M70.70M34.00M20.40M45.90M76.90M37.60M35.30M51.30M95.30M38.10M48.80M69.10M106.40M41.90M53.50M87.80M117.70M16.40M37.90M81.20M89.10M85.60M113.20M96.50M73.90M131.30M122.70M86.20M124.50M64.80M48.10M68.10M31.80M11.90M-51.80M10.20M-65.30M
Net Income 6.50M21.90M11.80M61.40M23.60M14.50M46.50M69.00M21.60M23.40M37.00M-3.40M27.00M31.20M43.40M78.10M30.80M36.50M61.30M68.60M10.50M24.10M54.30M56.70M57.60M87.10M61.60M49.50M88.10M76.50M57.10M88.10M50.90M7.60M40.90M17.40M7.60M-59.60M14.40M-52.00M
Diluted EPS 0.040.130.070.360.140.090.290.430.130.150.23-0.020.170.200.280.500.200.230.390.440.070.160.350.370.380.570.410.330.590.520.390.600.350.050.270.110.05-0.410.02-0.41
R&D Expense 37.20M37.50M34.30M-36.10M36.80M37.90M-37.60M40.30M40.60M-43.20M43.60M41.80M-46.40M48.50M46.10M-48.50M44.10M48.30M54.80M55.80M52.10M56.60M59.60M56.20M69.00M71.00M71.30M81.80M92.20M98.10M97.10M100.20M98.30M101.30M94.30M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.11B1.30B1.65B1.79B1.84B1.81B1.62B1.61B1.77B1.90B2.07B1.99B2.42B2.53B2.96B3.37B3.44B
Gross Profit 517.50M604.00M752.50M829.40M805.20M763.30M708.60M745.30M816.00M900.00M995.30M939.80M1.21B1.31B1.51B1.65B1.58B
Operating Income 136.70M155.70M155.60M156.00M148.20M105.40M145.70M181.80M219.50M262.40M300.90M248.30M413.30M432.70M436.90M253.10M68.20M
Net Income 81.20M95.40M92.30M77.50M80.10M56.70M101.60M153.60M78.60M179.70M197.20M157.80M277.10M296.60M427.20M113.10M-8.60M
Diluted EPS 0.490.580.550.460.480.330.600.950.491.141.261.021.811.992.900.76-0.15
R&D Expense 126.40M141.40M177.20M195.30M190.50M174.20M145.70M147.90M161.60M173.40M187.70M198.00M220.80M235.90M294.80M376.50M395.20M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.55B1.71B1.86B1.99B1.86B1.73B1.81B1.95B2.13B2.77B3.05B3.65B3.61B4.25B5.81B6.24B
Total Equity 312.70M418.80M524.70M621.50M706.60M846.10M765.90M726.10M686.40M725.40M896.60M906.80M961.20M1.07B1.11B1.38B1.78B2.46B
Cash & Equivalents 166.20M207.10M230.40M246.00M310.60M438.70M319.50M267.10M342.40M325.00M322.40M678.30M681.80M1.07B645.50M488.30M183.40M298.80M
Long Term Debt --301.00M303.10M337.20M355.00M355.00M---322.60M812.80M842.30M1.22B1.20B1.16B2.06B1.85B
Total Liabilities --------------2.48B2.84B3.99B3.73B
Current Liabilities --831.50M755.80M681.80M648.60M582.70M554.50M524.70M524.50M599.30M645.60M791.90M938.50M914.30M1.20B1.28B1.28B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ------229.20M130.80M154.40M239.70M213.40M332.20M282.40M274.40M350.10M251.30M134.10M
Investing Cash Flow -------102.40M-21.80M-30.20M-123.40M-158.40M-192.70M-192.40M-251.60M-326.00M-1.76B-196.50M
Financing Cash Flow -------169.40M-27.90M-159.00M-112.40M300.00M-161.60M318.70M-415.30M-193.40M1.23B135.10M
Capital Expenditure -16.30M-31.90M-61.60M-72.80M-50.30M-33.80M-34.20M-37.10M-43.70M-49.20M-73.00M-97.20M-92.00M-129.20M-106.90M-115.30M-90.80M
Free Cash Flow ------195.00M93.70M110.70M190.50M140.40M235.00M190.40M145.20M243.20M136.00M43.30M
Share Buybacks ------90.00M160.00M152.20M-142.30M123.20M153.30M263.10M152.30M010.00M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 46.4%46.3%45.6%46.3%43.8%42.2%43.6%46.3%46.2%47.5%48.0%47.3%50.0%51.6%51.0%49.0%45.9%
Operating Margin % 12.3%11.9%9.4%8.7%8.1%5.8%9.0%11.3%12.4%13.8%14.5%12.5%17.1%17.1%14.7%7.5%2.0%
Net Margin % 7.3%7.3%5.6%4.3%4.4%3.1%6.3%9.5%4.5%9.5%9.5%7.9%11.5%11.7%14.4%3.4%-0.3%
ROE % 19.4%18.2%14.9%11.0%9.5%7.4%14.0%22.4%10.8%20.0%21.7%16.4%25.9%26.6%31.0%6.3%-0.4%
ROCE % -21.7%16.3%13.3%11.1%8.2%12.4%14.2%15.4%17.2%14.2%11.0%15.2%16.0%14.3%5.6%1.4%

Shareholding Pattern

Insiders
26.97%
Institutions
95.85%
Public Float
131.24%

Top Institutional Holders

#Holder% HeldSharesValue
1 FMR, LLC 13.28% 20.24M $1.24B
2 Orbis Allan Gray Ltd 11.77% 17.94M $1.10B
3 Blackrock Inc. 7.49% 11.41M $700.30M
4 Pallas Capital Advisors Llc 6.22% 9.48M $582.22M
5 Vanguard Portfolio Management LLC 3.21% 4.89M $300.09M
6 Vanguard Capital Management LLC 3.19% 4.86M $298.31M
7 Sculptor Capital LP 3.04% 4.62M $283.93M
8 State Street Corporation 2.64% 4.02M $246.64M
9 Franklin Resources, Inc. 2.12% 3.23M $198.25M
10 Sachem Head Capital Management, LP 1.91% 2.92M $178.95M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BRKR

Google News ue, 08 Sep 2026

Bruker Corporation $BRKR Stock Holdings Lessened by VELA Investment Management LLC - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNTFNDZVVYVGdCcU9LQV9fdFdpbElJYWk4V21PQS1DVno5bmkyR0lkbnc1aUF0bWJxOVdwUlVMdGNySEY5QzE3SDlXbHkwY21EcG5QejhITXA2bGI3NlRjeVhDcGdsX01rSjJPYUZfWTZOWXZnekFxeDlaQzYwdzRVejF3Z25pUGFtTV9ZR2…

Google News ue, 04 Aug 2026

Bruker (BRKR) Stock Trades Down, Here Is Why - StockStory

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOOG9vRUFpbXBiUmE1RWlIMGhxWEl5ZlBXSVI2R2xfakdic3A4QWZ0a0tIeUNQaklfUm5SWmJmQWZuVmV5TXJTdGZBMC1tTVRYWUpqX3NaVkhlQUtfQ09ONnpQcUxkUlRXb0FjYlI4QTV5YnV3akhVZU1XSzJoTS1OZUNtVVhvLXQ3anRYcT…

Google News hu, 03 Sep 2026

Why Is Bruker (BRKR) Up 12.5% Since Last Earnings Report? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNWjNmdnVsSlRLSlVOTmJyc08zd01IbXFvUXozNmVKUC1MbVF0cUNOMllRT2NWMjBZU3UtQ1kyWHF2azFaRy1sbzNNT00wblkxcnRFRGxjSzZabGkyam1FbTlxbGczZ1FmSlEzbXctMnlNbDdQWkFYUFlMZ3NEZkN0XzR3emNhWTNYaVA4cX…

Google News Fri, 04 Sep 2026

Fusion plasma is hotter than the sun’s core. Bruker and Luvata will work to expand special wire supplies. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQZlVZNVZsaGxEcWFCQ0tOYWRCWDNnVUJTa1hzTjFQQS1VdVNQZVlfV1R4dmk3TzdybWJsZTVXNVpQYkpPWDJINkdCYVVYc0lkNVpHSGd5MmJTX0I0Z09UYWVfQUlkSjdadXc2ZzQwSVptUjR3T3psTVdaWmh0XzU4Yzl3SXRTYVFfd2t2NX…

Google News hu, 07 May 2026

BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down - Zacks Investment Research

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPNmRna1VFcXJJMmg5RlBPYjllYkpWMUFIa2Z5MGo2Rnl2WnBRUlFteWUwd0czT3ozdUVWVmxjVVBibm1XOTVNaUROVy1pbENkWTlMd20wWVplSmFBLWF0YnhPQmg5OXBtaTl6Qm5uNjdYVk9qYTB2Sl9lSXdvR0lpTzZncDIzbklqTldIYW…

Google News hu, 03 Sep 2026

Bruker (BRKR) Misses Q2 Estimates, Is It Still Only 1% Undervalued? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNT28xekhuZHFxRTBMU2tsaUxPa0JsMlo3ekRzMmtoNkFSWWhBZUR6T2Zwd3ZXX1Z1V2I2MDNCWHkzSzl4NUtjb2ltQVVEVmxScXl3QVI1Vm1aUmFzOUoxVGlpMUh2YnlpR1QwdnRNZUl1MG0yVzVLUmE0RHBaZjJ0eGpaNWxibmY0NE1pTk…

BRKR — Frequently Asked Questions

What is the current share price of Bruker Corporation (BRKR)?

As of 2026-09-19 21:16 PDT, Bruker Corporation (BRKR) trades at $58.37 on NasdaqGS. Its 52-week range is $29.21 to $64.34.

What is the market capitalisation of BRKR?

Bruker Corporation (BRKR) has a market capitalisation of $8.89B on NasdaqGS.

What is the P/E ratio of BRKR?

BRKR trades at a trailing price-to-earnings (P/E) ratio of -83.39. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.48.

Does BRKR pay a dividend?

Bruker Corporation (BRKR) currently offers a dividend yield of 0.34%.

What is the return on equity (ROE) of BRKR?

BRKR has a return on equity (ROE) of -3.00%. Its return on capital employed (ROCE) is 1.37%.

Is BRKR a good stock to buy?

This page provides a data-driven analysis of Bruker Corporation (BRKR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space